[go: up one dir, main page]

PE20090598A1 - Derivados de 2,3,4,9-tetrahidro-1h-carbazol como ligandos del receptor cb1 - Google Patents

Derivados de 2,3,4,9-tetrahidro-1h-carbazol como ligandos del receptor cb1

Info

Publication number
PE20090598A1
PE20090598A1 PE2008001393A PE2008001393A PE20090598A1 PE 20090598 A1 PE20090598 A1 PE 20090598A1 PE 2008001393 A PE2008001393 A PE 2008001393A PE 2008001393 A PE2008001393 A PE 2008001393A PE 20090598 A1 PE20090598 A1 PE 20090598A1
Authority
PE
Peru
Prior art keywords
tetrahydro
alkyl
carbazol
cycloalkyl
pyran
Prior art date
Application number
PE2008001393A
Other languages
English (en)
Inventor
Sara Beha
William Brown
Shawn Johnstone
Ziping Liu
Daniel Page
Miroslaw Tomaszewski
Zhong-Yong Wei
Shi Yi Yue
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090598A1 publication Critical patent/PE20090598A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE 2,3,4,9-TETRAHIDRO-1H-CARBAZOL DE FORMULA (I) DONDE Y ES (a), (b), (c), ENTRE OTROS, EN DONDE R3 Y R4 SON CADA UNO H, AMINO, -C(=O)-O-ALQUILO(C1-C6), ENTRE OTROS; R5 ES H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C6); R6 ES H, CN, NO2, NH2, ALCOXI(C1-C6), ENTRE OTROS; Q ES ALQUILENO(C1-C6), ALQUILIDENO(C1-C6), ENTRE OTROS; m ES DE 0 A 3; n ES DE 1 A 3; R1 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), -S(=O)2-ALQUILO(C1-C6), ENTRE OTROS; R2 ES HETEROCICLOALQUILO(C3-C6), HETEROCICLOALQUIL(C3-C6)-ALQUILO(C1-C4), ARILO(C6-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[2-(CICLOPROPILAMINO)-2-OXOETIL]-N,9-DIMETIL-3-(TETRAHIDRO-2H-PIRAN-4-IL)-2,3,4,9-TETRAHIDRO-1H-CARBAZOL-6-CARBOXAMIDA, N-ETIL-N-[2-(ETILAMINO)-2-OXOETIL]-9-METIL-3-(TETRAHIDRO-2H-PIRAN-4-IL)-2,3,4,9-TETRAHIDRO-1H-CARBAZOL-6-CARBOXAMIDA, N-CICLOPROPIL-2-(1-(9-METIL-3-(TETRAHIDRO-2H-PIRAN-4-IL)-2,3,4,9-TETRAHIDRO-1H-CARBAZOL-6-CARBONIL)AZETIDIN-3-IL)ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR CANNABINOIDE CB1 SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR, ESCLEROSIS MULTIPLE, COREA HUNTINGTON, ENFERMEDAD DE ALZHEIMER
PE2008001393A 2007-08-17 2008-08-15 Derivados de 2,3,4,9-tetrahidro-1h-carbazol como ligandos del receptor cb1 PE20090598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95647807P 2007-08-17 2007-08-17

Publications (1)

Publication Number Publication Date
PE20090598A1 true PE20090598A1 (es) 2009-06-10

Family

ID=39930420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001393A PE20090598A1 (es) 2007-08-17 2008-08-15 Derivados de 2,3,4,9-tetrahidro-1h-carbazol como ligandos del receptor cb1

Country Status (16)

Country Link
US (2) US20090062251A1 (es)
EP (1) EP2190838A1 (es)
JP (1) JP2010536737A (es)
KR (1) KR20100061491A (es)
CN (1) CN101827838A (es)
AR (1) AR067954A1 (es)
AU (1) AU2008290325A1 (es)
BR (1) BRPI0815493A2 (es)
CA (1) CA2696697A1 (es)
CL (1) CL2008002431A1 (es)
MX (1) MX2010001574A (es)
PE (1) PE20090598A1 (es)
RU (1) RU2010102992A (es)
TW (1) TW200908963A (es)
UY (1) UY31294A1 (es)
WO (1) WO2009024819A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US8383615B2 (en) * 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
IN2012DN05122A (es) * 2009-12-11 2015-10-23 Bayer Ip Gmbh
JP5841361B2 (ja) * 2011-06-29 2016-01-13 壽製薬株式会社 三環性化合物及びそれを含有する医薬組成物
JP6106452B2 (ja) * 2012-12-05 2017-03-29 公益財団法人微生物化学研究会 化合物、及びその製造方法、並びにリン酸オセルタミビルの製造方法
US9714234B2 (en) 2013-06-25 2017-07-25 Bristol-Myers Squibb Company Carbazole carboxamide compounds
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
CA2965517C (en) 2014-10-24 2023-05-02 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
WO2016065222A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
PH12017500724B1 (en) 2014-10-24 2023-07-05 Bristol Myers Squibb Co Carbazole derivatives
EP4110463A1 (en) * 2020-02-24 2023-01-04 Galyan Bio, Inc. Indole compounds for the treatment of neurodegenerative diseases
EP4140481A1 (en) * 2021-08-26 2023-03-01 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof
WO2023025915A1 (en) * 2021-08-25 2023-03-02 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
JP2005527586A (ja) * 2002-04-05 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド 置換アリールアミド
CN102030750A (zh) * 2005-03-22 2011-04-27 阿斯利康(瑞典)有限公司 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002

Also Published As

Publication number Publication date
TW200908963A (en) 2009-03-01
AR067954A1 (es) 2009-10-28
US20090062251A1 (en) 2009-03-05
EP2190838A1 (en) 2010-06-02
MX2010001574A (es) 2010-03-15
AU2008290325A1 (en) 2009-02-26
CA2696697A1 (en) 2009-02-26
UY31294A1 (es) 2009-03-31
JP2010536737A (ja) 2010-12-02
CL2008002431A1 (es) 2009-06-05
CN101827838A (zh) 2010-09-08
US20110160180A1 (en) 2011-06-30
RU2010102992A (ru) 2011-09-27
KR20100061491A (ko) 2010-06-07
WO2009024819A1 (en) 2009-02-26
BRPI0815493A2 (pt) 2015-02-10

Similar Documents

Publication Publication Date Title
PE20090598A1 (es) Derivados de 2,3,4,9-tetrahidro-1h-carbazol como ligandos del receptor cb1
CA2781140C (en) Proline derivatives for use to treat hepatitis c infection
RU2351589C2 (ru) Производные n-[фенил(алкилпиперидин-2-ил)метил]бензамида и их применение в терапии
RU2012104214A (ru) Противовирусные соединения и способы их получения и применения
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
PE20081314A1 (es) COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
JP2005504039A5 (es)
PE20070336A1 (es) Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
EP2528893A2 (en) Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
PE20070751A1 (es) Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl
RU2010119554A (ru) Замещенные n-фенил-бипирролидинмочевины и их терапевтическое применение
CA2471880A1 (en) 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
AR078958A1 (es) Derivados de oxazolina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por los receptores taar1
AU2008304867B2 (en) Indazole acrylic acid amide compound
DE602006020273D1 (de) Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon
EA201070495A1 (ru) МОДУЛЯТОРЫ АКТИВНОСТИ γ-СЕКРЕТАЗЫ ИЗ ГРУППЫ ПИПЕРИДИНИЛА И ПИПЕРАЗИНИЛА
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
PE20080206A1 (es) Derivados de aril y heteroaril-etil-acilguanidina como inhibidores de renina
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
ATE399164T1 (de) Antagonisten des opioidrezeptors
DE602007010041D1 (de) Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
ES2242866T3 (es) Derivados de bencimidazol para el tratamiento de enfermedades asociadas con la activacion de las microglias, tales como enfermedades inflamatorias, alergicas, infecciosas o autoinmunitarias.

Legal Events

Date Code Title Description
FC Refusal